Open AccessClinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy
Author(s) -
Melissa Bersanelli,
Teresa Zielli,
Fabiana Perrone,
Chiara Casartelli,
Fabiana Pratticò,
Elena Rapacchi,
Roberta Camisa,
Michele Tognetto,
Alberto Clemente,
Diana Giannarelli,
Sara Elena Rebuzzi,
Alessandro Leonetti,
Paola Bordi,
Marcello Tiseo,
Sebastiano Buti
Publication year - 2020
Publication title -
immunotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.127
H-Index - 48
eISSN - 1750-7448
pISSN - 1750-743X
DOI - 10.2217/imt-2020-0211
Subject(s) - medicine , incidence (geometry) , prospective cohort study , cancer , pneumonitis , cohort study , cohort , disease , pneumonia , lung cancer , pediatrics , lung , physics , optics
Aim: Evaluating the incidence and course of COVID-19 in cancer patients treated with immunotherapy. Patients & methods: We reported the influenza-like illness events with diagnosis of COVID-19 within the patient cohort enrolled in the prospective observational multicenter INVIDIa-2 study in the single center of Parma. Results: Among 53 patients, eight experienced influenza-like illness during the influenza season 2019/2020, and three of them had diagnosis of COVID-19. They were males, elderly, with cardiovascular disease. Radiological features of COVID-19 pneumonitis were found in all of three cases, although the pharyngeal swab resulted positive in only two. Two of these three patients died due to respiratory failure. Conclusion: Cancer patients are at high risk of severe events from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.